Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Expands By 20.5%

Key Points

• Tiziana Life Sciences Ltd experienced a significant increase in short interest by 20.5% in August, bringing the total to 791,900 shares.
• The company's stock traded up to $1.78, with a short-interest ratio of 2.3 days, suggesting a moderate level of short selling activity.
• Institutional investors have shown increased interest in Tiziana, with notable purchases including a new position from Dauntless Investment Group valued at approximately $1.88 million.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 791,900 shares, an increase of 20.5% from the August 15th total of 657,200 shares. Based on an average daily volume of 345,800 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.3% of the company's stock are short sold. Currently, 1.3% of the company's stock are short sold. Based on an average daily volume of 345,800 shares, the days-to-cover ratio is presently 2.3 days.

Hedge Funds Weigh In On Tiziana Life Sciences

A number of large investors have recently bought and sold shares of TLSA. Dauntless Investment Group LLC acquired a new position in Tiziana Life Sciences during the 1st quarter worth approximately $1,879,000. Jane Street Group LLC boosted its position in Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Tiziana Life Sciences during the 1st quarter worth approximately $156,000. Bison Wealth LLC acquired a new position in Tiziana Life Sciences during the 4th quarter worth approximately $30,000. Finally, Marshall Wace LLP acquired a new position in Tiziana Life Sciences during the 2nd quarter worth approximately $39,000.

Tiziana Life Sciences Stock Performance

NASDAQ TLSA remained flat at $1.82 during trading hours on Monday. The company had a trading volume of 268,768 shares, compared to its average volume of 575,061. Tiziana Life Sciences has a twelve month low of $0.63 and a twelve month high of $2.60. The business's 50 day moving average price is $1.88 and its 200-day moving average price is $1.53.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.